ClinicalTrials.gg
Active, not recruitingNCT04276532Updated May 12, 2026

Sentinel Lymph Node Sampling for Patients With Middle-high Risk Endometrial Cancer Confined to the Uterus

An interventional study of sentinel lymph node sampling (SLN) and pelvic lymphonodectomy (PLN) in Middle-high Risk Endometrial Cancer, Sentinel Lymph Node Sampling and Prognosis, sponsored by Xiaojun Chen. Active, not recruiting at 1 site in China. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Xiaojun Chen · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
780
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 172 studies in Endometrial Neoplasms with a site in China — 100 open to participants now, 122 under way, 21 of them phase 3. Endometrial Neoplasms · China.

Planned enrollment
10th of 142
780 · median 113
Started
2020
with 14 others
No phase
33 of 172
21 open now
Primary completion
2027-01
later than 53 of 121 live
Registered
30th of 172
by date

Among the 172 studies in Endometrial Neoplasms with a site in China, this one is the 10th largest by planned enrollment of the 142 interventional ones that give a count, is one of 15 that started in 2020, is one of 33 with no phase, reaches primary completion later than 53 of the 121 other live ones, and was the 30th registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

100 of the 172 studies in Endometrial Neoplasms with a site in China are open now. Recruiting first, the newest first:

95 more — sign in →

All 100 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 172 studies in Endometrial Neoplasms with a site in China, or all of them as a file.
02

Study summary

Aim To investigate the effect of sentinel lymph node (SLN) sampling on the prognosis of patients with middle-high risk endometrial cancer obviously confined to the uterus before surgery.

Read the detailed description

Aim to investigate the effect of sentinel lymph node (SLN) sampling on the prognosis of patients with middle-high risk endometrial cancer obviously confined to the uterus before surgery.

Rationale The diagnostic value of sentinel lymph node sampling has been widely approved. NCCN guideline suggested that "SLN mapping can be considered for the surgical staging of apparent uterine-confined malignancy when there is no metastasis demonstrated by imaging studies or no obvious extrauterine disease at exploration". However, the role of SLN in the prognosis of mid-high risk endometrial cancer clinically confined to the uterus is unclear. There are big concerns that SLN sampling only without lymph node dissection might miss isolated para-aortic lymph node metastasis or remain lymph node with metastasis other than SLN unremoved and thus affect the prognosis of patients. NCCN also suggested that "Para-aortic nodal evaluation from the inframesenteric and infraenal regions may also be utilized for staging in women with high-risk tumors such as deeply invasive lesions, high-grade histology, and tumors of serous carcinoma, clear cell carcinoma or carcinosarcoma. Thus, it is necessary to carry out a randomized trail to investigate the role of SLN in the prognosis of middle-high risk endometrial cancer obviously confined to the uterus before surgery.

Ethics This study were approved by the Ethics Committees of Obstetrics and Gynecology Hospital of Fudan University and all other institutes. Before initiation of study procedures, written informed consent will be obtained from each patient regarding risks of treatments and agreement of using their clinical data for research purpose.

Randomization and Treatment This is a multicentered, open-label, randomized clinical trial. Randomization will be carried out in each center. A computer-based procedure of simple randomization (SPSS for Mac, version 22.0; IBM ) will be used for participant enrollment and randomization. Before an individual is successfully enrolled, her treatment assignment will remain concealed. This trial will be open label: patients and study physicians were aware of treatment assignment.

Eligible patients in each center will be randomly assigned (1:1) to receive:

1. Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus pelvic lymphonodectomy (PLN) with para-aortic sampling, or 2. Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus sentinel lymph node sampling (SLN).

  1. The principles of surgery procedures and post-operative adjuvant therapies will follow the latest NCCN guidelines.
  2. Surgery carried out by laparotomy, laparoscope, or robotic surgery are accepted.
  3. Colored dyes including indocyanine green (ICG) (preferred), methylene blue, carbon nanotube for sentinel lymph node are accepted.
  4. Postoperative adjuvant treatments are carried out following the latest NCCN or ESGO guidelines according to doctors' choice.

Statistical analyses On the basis of data from previous studies (GOG249, FRACOGYN), the 2-year PFS is expected to be 88% in the PLN group and 87% in SLN group. SLN would be considered as inferior to PLN if the 2-year PFS in SLN group is higher than 80%. An accrual of 780 patients in 3 years will provide the study with adequate power (80%) to detect a clinically relevant absolute difference of 8% in 2-year PFS (88% vs 80%) between both groups (one-sided test, a=0.025), with a lost follow up rate ≤10% . Analyses will be done firstly by intention to treat.

03

Conditions studied

  • Middle-high Risk Endometrial Cancer
  • Sentinel Lymph Node Sampling
  • Prognosis

Keywords

  • Middle-high risk endometrial cancer
  • Sentinel lymph node sampling
  • Pelvic lymphadenectomy
  • Prognosis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Older than 18 years old;
  2. Clinically diagnosed (by pre-surgical pathology and radiology) as primary endometrial cancer confined to uterus with middle-high risk factors:

    1. disease limited to the uterus on image study (MRI, CT or ultrasound);
    2. including all histological types of endometrial cancer (endometrioid, serous, clear cell, carcinosarcoma, and undifferentiated carcinoma); not including uterine sarcoma
    3. excluding low-risk endometrial cancer (endometrioid G 1-2 with pre-surgical endometrial lesion≤2cm and myometrial invasion \<50%);
    4. with one or more middle-high risk factors including: endometrioid endometrial cancer G3, myometrial invasion ≥50%, tumor size≥2cm, type II endometrial cancer, molecular classification of p53abn, LVSI;
    5. diagnosis should be confirmed by at least two senior clinicians;
  3. Be able to undergo staging surgery.

Exclusion criteria

Exclusion Criteria:

  1. During pregnancy or perinatal period;
  2. With synchronous or other malignancies than endometrial cancer in 3 years, except for non-melanoma skin cancer;
  3. With history of important organs transplantation;
  4. With immune diseases requiring taking
  5. With severe mental illness or brain function disorders
  6. With history of drug abuse;
  7. Allergic to contrast agent;
  8. Still participating in other clinical trials;
  9. Not willing to accept surgery or trial protocol;
  10. Not eligible for surgery;
  11. Had hysterectomy, chemotherapy, radiotherapy, or hormone therapy before the trail;
  12. Had retroperitoneum lymph node dissection for other reasons.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
780 participants (estimated)

Study arms

  • Experimental
    Sentinel lymph node sampling

    Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus sentinel lymph node sampling (SLN)

    Procedure: sentinel lymph node sampling (SLN)

  • Active comparator
    Pelvic lymphadenectomy

    Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus pelvic lymphonodectomy (PLN) with or without para-aortic sampling

    Procedure: pelvic lymphonodectomy (PLN)

Interventions

  • Proceduresentinel lymph node sampling (SLN)

    Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus sentinel lymph node sampling (SLN). 1. The principles of surgery procedures and post-operative adjuvant therapies will follow the latest NCCN guidelines; 2. Surgery carried out by laparotomy, laparoscope, or robotic surgery are accepted; 3. Colored dyes including indocyanine green (ICG) (preferred), methylene blue, carbon nanotube for sentinel lymph node are accepted.

  • Procedurepelvic lymphonodectomy (PLN)

    Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus pelvic lymphonodectomy (PLN) with or without para-aortic sampling

06

What researchers measure

Primary outcomes

  1. The 2-year progression-free survival (2-year PFS)

    The percentage of patients who have first relapse within 2 years after surgery (SLN or LND)

    Time frame: 2 years

Secondary outcomes

  1. The 5-year PFS

    The percentage of patients who have first relapse within 5 years after surgery (SLN or LND)

    Time frame: 5 years

  2. The 5-year overall survival (OS)

    The percentage of patients who die within 5 years after surgery (SLN or LND)

    Time frame: 5 years

  3. Adverse effect and quality of life (QOL)

    The occurence rate of each adverse effects related to surgery (SLN or LND, the scores of each QOL survay

    Time frame: Adverse effect: during the surgery, 30 days after surgery; QQL: 1 month after surgery, 6 months, 12 months after surgery

07

Study locations

1 site
  • Tenth People's Hospital Affiliated to Tongji University
    Shanghai, Shanghai Municipality 200072, China
08

References and documents

Publications

  • Guan J, Xue Y, Zang RY, Liu JH, Zhu JQ, Zheng Y, Wang B, Wang HY, Chen XJ. Sentinel lymph Node mapping versus systematic pelvic lymphadenectomy on the prognosis for patients with intermediate-high-risk Endometrial Cancer confined to the uterus before surgery: trial protocol for a non-inferiority randomized controlled trial (SNEC trial). J Gynecol Oncol. 2021 Jul;32(4):e60. doi: 10.3802/jgo.2021.32.e60. PubMed 34085796 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2020 (actual). Primary completion is estimated for Jan 2027, 83 months after the start.

Of 194 non-industry interventional studies with no phase under Endometrial Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 76. This study's planned 83 months is above that.

Counting every sponsor, half of 200 studies reached it within 43 months; a quarter within 19 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2020
First posted
Feb 19, 2020
StartActual
Feb 13, 2020
Primary completionEst.
Jan 26, 2027
CompletionEst.
Feb 12, 2030
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04276532
Lead sponsor
Xiaojun Chen
Collaborators
Fudan University, Tongji Hospital, West China Second University Hospital, Sun Yat-Sen University Cancer Center, Chongqing University Cancer Hospital
Responsible party
Xiaojun Chen (Vice President of Obstetrics and Gynecology Hospital of Fudan University, Fudan University) — Sponsor-investigator
First posted
Feb 19, 2020
Start date
Feb 13, 2020
Primary completion
Jan 26, 2027 (estimated)
Completion
Feb 12, 2030 (estimated)
Last update
May 12, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion